Skip to content
Roboearth – Lifestyle
Author:
SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer
September 25, 2026
SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer
September 2, 2026
SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 11, 2026
SELLAS Life Sciences to Participate in Upcoming Investor Conferences
May 14, 2026
SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 12, 2026
SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009
March 12, 2026